CCR3 is a target for age-related macular degeneration diagnosis and therapy - Test2 - elhamkhani - TriplyDB

CCR3 is a target for age-related macular degeneration diagnosis and therapy

CCR3 is a target for age-related macular degeneration diagnosis and therapy

http://www.wikidata.org/entity/Q24338258

about

DICER1 loss and Alu RNA induce age-related macular degeneration via the NLRP3 inflammasome and MyD88 AMD Genetics in India: The Missing Links Regulation of signaling events involved in the pathophysiology of neovascular AMD Genetics of immunological and inflammatory components in age-related macular degeneration Mechanisms of age-related macular degeneration AAV2 delivery of Flt23k intraceptors inhibits murine choroidal neovascularization Nanomedicine in the application of uveal melanoma LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling.Study in vivo intraocular biocompatibility of in situ gelation hydrogels: poly(2-ethyl oxazoline)-block-poly(ε-caprolactone)-block-poly(2-ethyl oxazoline) copolymer, matrigel and pluronic F127 Circulating Autoantibodies in Age-Related Macular Degeneration Recognize Human Macular Tissue Antigens Implicated in Autophagy, Immunomodulation, and Protection from Oxidative Stress and Apoptosis Utilizing targeted gene therapy with nanoparticles binding alpha v beta 3 for imaging and treating choroidal neovascularization CCR3 and choroidal neovascularization The mouse retina as an angiogenesis model.Targeted intraceptor nanoparticle therapy reduces angiogenesis and fibrosis in primate and murine macular degeneration.Integrative pathway-centric modeling of ventricular dysfunction after myocardial infarction.Animal models of choroidal and retinal neovascularization.Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells.Regulation of ocular angiogenesis by Notch signaling: implications in neovascular age-related macular degeneration.The Immune System and AMD Histamine H4 receptor as a new therapeutic target for choroidal neovascularization in age-related macular degeneration The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration Age-related macular degeneration: insights into inflammatory genes.Selective activation of the prostaglandin E2 circuit in chronic injury-induced pathologic angiogenesis Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity.Milligram production and biological activity characterization of the human chemokine receptor CCR3.DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration A Novel Platelet-Activating Factor Receptor Antagonist Inhibits Choroidal Neovascularization and Subretinal Fibrosis.Age-related macular degeneration and the other double helix. The Cogan Lecture.Exosomes from retinal astrocytes contain antiangiogenic components that inhibit laser-induced choroidal neovascularization.A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.Rap1 GTPase activation and barrier enhancement in rpe inhibits choroidal neovascularization in vivo.Copy number variations in candidate genes in neovascular age-related macular degeneration.Blood expression levels of chemokine receptor CCR3 and chemokine CCL11 in age-related macular degeneration: a case-control study.Chemokine mediated monocyte trafficking into the retina: role of inflammation in alteration of the blood-retinal barrier in diabetic retinopathy.Upregulation of CCR3 by age-related stresses promotes choroidal endothelial cell migration via VEGF-dependent and -independent signaling Plasma-activated medium suppresses choroidal neovascularization in mice: a new therapeutic concept for age-related macular degeneration.Suppression of Laser-Induced Choroidal Neovascularization by the Oral Medicine Targeting Histamine Receptor H4 in Mice.Increased CCL24/eotaxin-2 with postnatal ozone exposure in allergen-sensitized infant monkeys is not associated with recruitment of eosinophils to airway mucosa Novel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability.Inflammatory Mechanisms of Age-related Macular Degeneration.

P2860

0cfae2c3109081a7094280ae689de5aa88bd7b74 24d565e41927c13af45097619069966b46fd8775 4997f78cab6f6273ade1f793a377744cb3aaaf3e 4bdddc93d6923cd398fd4a244a7d1808f6d14146 602ad90d22e06d897c4d6ccbc212f6db01e3b9e8 738988234bf10ab1d5ebb9c2f0e83dd2401dfc6f 76586c29e223b9c85f89195cdc20739230bc8cab 988704096c54b4d865dcd19f9ddab953285218c0 bb18daf8493facae0a4c6c8a1c2d79bab9ea6344 ea82c49c9b0e9944cc2fa8b374e48156829ebba3

P248

Q24621930-35EB7914-4985-4B63-9EBE-2AC59B2C56B7 Q26744092-740ED21E-867E-4CC7-A8FA-8C2CDC6ED9F7 Q26751293-9FDD2CEE-EF43-41F9-B4BE-EE1DC252C2F7 Q26849231-14C8B861-E429-466C-8595-F3BF05989AC2 Q27000182-1A2153C8-C2B9-40CB-B4B9-3BAA89BF31F1 Q27318539-FAE4907E-DF28-4D49-B21A-4AB06B495C8B Q28079572-F5A4E360-CD7C-4FC7-83A0-B34C8EE383C5 Q28508560-BA88CA5A-3743-4A29-AB96-C5B0A57FEA2A Q28534435-065E3902-4F2D-465E-95D5-FC1C8BF79488 Q28551885-F58F7B15-A421-4CD0-B2CA-B5C076534DA7 Q28740612-3E275E46-3988-49C1-BA4D-F4CC9D1F9D09 Q28742748-2CDE1EFD-D815-4418-9C46-2156E52890E0 Q30495106-69DF9CB9-48D8-43EB-B11C-688530509328 Q30539153-2B90F3A1-4C41-46D5-B345-7F3D6F654C18 Q33543006-95A4682A-482C-4C03-A6C8-3930A7F31C5E Q33582933-6CB08362-DD72-4FA4-9E61-DB7304183AAA Q33728338-D6133E32-CF70-4413-9028-C75A0E485DCE Q33791749-14BB9F00-F468-411D-B4B1-FE7A36E57F86 Q34003743-9CAC0B06-1004-437E-A33A-3D48D9BA2E84 Q34025192-119F0B16-F780-4E1B-BB12-1B9D63467956 Q34281402-BBF562DA-5387-4AA3-914F-8F1C26445C2F Q34588628-9451C888-9F6D-4C37-B99C-6883F4AD0B95 Q34662175-B779B7F4-B562-4E1F-8B85-3EF276D6983E Q34757980-E023DD73-85C8-4C9B-8149-0421CA23161F Q34766579-E471B0E9-416F-431C-A63E-D8F22C2D13A0 Q34796058-FC507419-6FEF-47A9-9F88-223F43B8A984 Q34797862-D70B201E-DE08-4D44-8536-C6641354A12C Q34824054-2E89550D-FF30-4EAD-ADEF-82B83D1D964E Q34909956-EFD4D735-F979-41D3-B61D-0A6A94136EE1 Q34973743-F86397F8-6ACE-40F4-992C-5EA03E4532B2 Q34988793-B365C7C1-56C9-4CA1-9083-23F05FDCEE1A Q35027522-3BDF3F6C-826F-4296-B2A2-0CC0F43A99A1 Q35103889-434BC847-0C7B-4F4D-AAE4-B55892B3C64B Q35346991-D18C5FEB-60F9-49DC-887F-B627E564F420 Q35522994-91FEDDE6-3225-44FC-920A-7C25497F7A63 Q35540652-4D2D0F8A-AAB1-4E6C-A87E-CE168115D142 Q35577903-273DED4D-9A68-4C62-9DAE-5B265224F0F9 Q35581099-93A1E258-4A68-4814-8986-82708F1C961B Q35696092-EEEDBB89-C7F1-486A-A8E3-BA2B17BD0B93 Q35755942-E6940262-455F-4F60-916D-6BD7DB5DD716

P2860

CCR3 is a target for age-related macular degeneration diagnosis and therapy

http://www.wikidata.org/entity/Q24338258

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

CCR3 is a target for age-related macular degeneration diagnosis and therapy

@ast

CCR3 is a target for age-related macular degeneration diagnosis and therapy

@en

CCR3 is a target for age-related macular degeneration diagnosis and therapy

@en-gb

CCR3 is a target for age-related macular degeneration diagnosis and therapy

@nl

type

label

CCR3 is a target for age-related macular degeneration diagnosis and therapy

@ast

CCR3 is a target for age-related macular degeneration diagnosis and therapy

@en

CCR3 is a target for age-related macular degeneration diagnosis and therapy

@en-gb

CCR3 is a target for age-related macular degeneration diagnosis and therapy

@nl

prefLabel

CCR3 is a target for age-related macular degeneration diagnosis and therapy

@ast

CCR3 is a target for age-related macular degeneration diagnosis and therapy

@en

CCR3 is a target for age-related macular degeneration diagnosis and therapy

@en-gb

CCR3 is a target for age-related macular degeneration diagnosis and therapy

@nl

P1433

Q24338258-DAAD0CC0-4557-4A22-9264-EC8A5CB9C195

P1476

Q24338258-29DDBC2C-380E-4843-91AB-40389A049688

P2093

Q24338258-0141B7D2-6763-469F-B572-B8B8415A2B43

Q24338258-07A90A0E-3181-4B9C-B241-FB80B94339D7

Q24338258-0BF1F314-5752-4247-91A5-B652738FEED3

Q24338258-23C3F08F-7ED0-4197-AC01-447EB6DDC7E3

Q24338258-286A204A-B31D-43AC-A1D6-2F8DF3876207

Q24338258-28FE7F39-5570-428C-BC70-3F198BE752B3

Q24338258-2B17C9AD-5888-411A-B2EA-B6952DF18CE6

Q24338258-2B264885-1914-4FFA-A2BE-DD80D2058A80

Q24338258-35151D6E-883F-4F6B-A280-E1BFF7C50485

Q24338258-37EE4CA5-E3A3-445A-A92E-C461C107D7F0

P2860

Q24338258-081813C7-2B48-427D-9D6C-E453B9F22057

Q24338258-0C946886-B55A-48B0-B4E3-E131CBF9C996

Q24338258-103B0F0B-FCAA-4837-BEFB-52104AA04D4C

Q24338258-12222500-AB86-473F-89CE-70E867054DD5

Q24338258-1534C7F2-38E7-426F-8C1E-B5B607B515EA

Q24338258-18F66100-B807-491B-8F8E-AAFBC3B72D63

Q24338258-1AF51F8B-BA3C-4C69-BCCE-9BAD93B797F2

Q24338258-1E9470B5-5D23-458C-85BD-3CA1C4727F51

Q24338258-21E692A2-7FB2-4A4D-9A1F-27532D4650BC

Q24338258-24F25AB2-FCF0-4225-888F-D78CE645317E

P2888

Q24338258-5451B054-2BA9-42D7-8C47-71D35B1E5914

P304

Q24338258-39533E1C-C2C1-423F-8136-145FBA7F8CFD

P31

Q24338258-4107736D-8636-4658-8B09-147217B4F4A0

P3181

Q24338258-91A977D0-02F4-43F3-B96D-32D722F9BA42

P356

Q24338258-2D0A6567-E55D-4F2F-89C9-D0DA34B56AD3

P407

Q24338258-13DD1A7E-46EB-4DBF-A959-F43E506E7BA6

P433

Q24338258-704829D4-7FB6-4B13-920A-2990AEDC551E

P478

Q24338258-FB1C00BD-ED39-48C3-A94C-133C7419BCDA

P50

Q24338258-31142BAD-DAC1-4E9A-AF14-619E2001758D

Q24338258-B377DD2E-6210-4054-9497-FF6923EAE7DD

P577

Q24338258-19919227-5CC4-4C6A-8A24-8588BA30BFB0

P5875

Q24338258-32A7AD19-1A95-4273-942F-6BB828A81E26

P6179

Q24338258-1759C618-EEE3-44D4-B170-66D8DF2DBDF6

P698

Q24338258-450D97FB-8C05-4236-9A23-0ACECBD71D95

P921

Q24338258-00851ED6-A359-408C-BAFE-0299B63C0268

Q24338258-0213ACF8-D953-4A09-B7EF-3A3665D3FBB7

Q24338258-0D3ED0A5-AD47-4773-A124-E1779C3CD6AB

Q24338258-1AF061F6-D602-4E49-A1CF-270EA52D97A1

Q24338258-1c439d2e-00a0-45e9-a05c-947c50e274ef

Q24338258-89CCB82B-D91B-46CE-A7AB-576D3AFE789E

Q24338258-989CE5CC-B08B-496F-9A7C-F23468BC9639

Q24338258-9F1DA313-8F9C-4915-86E9-6FA3D0884A09

Q24338258-A249A132-3262-4D47-B61D-B21EED4AC146

P932

Q24338258-CF5791DA-92AF-4447-8464-E5D11BC0AB47

P3181

P356

P1433

P1476

CCR3 is a target for age-related macular degeneration diagnosis and therapy

@en

P2093

Alison A Humbles

http://www.w3.org/2001/XMLSchema#string

Ariel Munitz

http://www.w3.org/2001/XMLSchema#string

Atsunobu Takeda

http://www.w3.org/2001/XMLSchema#string

Balamurali K Ambati

http://www.w3.org/2001/XMLSchema#string

Brian J Raisler

http://www.w3.org/2001/XMLSchema#string

Craig J Gerard

http://www.w3.org/2001/XMLSchema#string

Hiroki Kaneko

http://www.w3.org/2001/XMLSchema#string

Jayakrishna Ambati

http://www.w3.org/2001/XMLSchema#string

John D Wright

http://www.w3.org/2001/XMLSchema#string

Judit Z Baffi

http://www.w3.org/2001/XMLSchema#string

P2860

Genes expressed in human tumor endothelium

An animal model of age-related macular degeneration in senescent Ccl-2- or Ccr-2-deficient mice

Drusen complement components C3a and C5a promote choroidal neovascularization

Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization

Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation

Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

Ranibizumab for neovascular age-related macular degeneration

P2888

P304

225-230

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

737897

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NATURE08151

http://www.w3.org/2001/XMLSchema#string

P407

P433

7252

http://www.w3.org/2001/XMLSchema#string

P478

460

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26291587

http://www.w3.org/2001/XMLSchema#string

P6179

1053680142

http://www.w3.org/2001/XMLSchema#string

P698

19525930

http://www.w3.org/2001/XMLSchema#string

P921

positive regulation of GTPase activity

Chemokine (C-C motif) ligand 11

C-C motif chemokine ligand 24

C-C motif chemokine receptor 3

C-C motif chemokine ligand 26

Chemokine (C-C motif) receptor 3

Chemokine (C-C motif) ligand 24

C-C motif chemokine ligand 11

P932

2712122

http://www.w3.org/2001/XMLSchema#string